Inactive Instrument

News GlaxoSmithKline plc London S.E.

Stocks

Pharmaceuticals

End-of-day quote London S.E. Other stock markets
- ^GBX	-

08-06	LifeMine Therapeutics, Inc. announced that it has received $188 million in funding from a group of investors	CI
08-06	US FDA approves first mRNA flu shot from Moderna	RE

All News

Mentions Relevance

08-06	LifeMine Therapeutics, Inc. announced that it has received $188 million in funding from a group of investors	CI
08-04	ViiV Healthcare Launches “Do It For Future You” Campaign Inspiring People to Prioritize Their Sexual Health and Future	BU
08-04	GSK : JP Morgan gives a Sell rating	ZD
08-03	GSK India first-quarter profit rises on steady vaccine demand	RE
08-03	GSK : Buy rating from Bernstein	ZD
07-30	GSK global supply chain director sells 38,000 shares	AN
07-30	GSK, Relation Therapeutics to Collaborate on Human Cellular Perturbation Data	MT
07-30	GSK : Deutsche Bank gives a Neutral rating	ZD
07-30	GSK, Relation Therapeutics sign up to $110 million AI drug discovery deal	RE
07-30	Relation Therapeutics Limited and Glaxosmithkline plc Announce Expanded Collaboration to Generate Large-Scale Human Cellular Perturbation Datasets	CI
07-30	GSK, Relation Therapeutics Collaborate on Human Cellular Data Project	MT
07-30	Goldman Sachs still cautious about GSK
07-29	GSK's ViiV Healthcare Highlights New Long-Acting Injectable Data on Cabenuva in HIV Treatment	MT
07-29	GSK : DZ Bank remains Neutral	ZD
07-29	GSK : JP Morgan reaffirms its Sell rating	ZD
07-29	GSK plc, Q2 2026 Earnings Call, Jul 28, 2026
07-28	GSK plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-28	Gsk plc Declares Second Interim Dividend for the Second Quarter of 2026, Payable on 8 October 2026	CI
07-28	GSK plc: Another beat; we appreciate the new CEO's aggressive intent
07-28	GSK Licensor's Late-Stage China Study for Risvutatug Rezetecan in Bone Cancer Meets Primary Endpoint	MT
07-28	GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline -- Update	DJ
07-28	GSK : JP Morgan gives a Sell rating	ZD
07-28	GSK : Bernstein maintains a Buy rating	ZD
07-28	GSK : Jefferies remains its Buy rating	ZD
07-28	GSK to Build New Global Research Center in Cambridge	MT